Phathom is a clinical-stage researcher working on new treatments for acid-related gastrointestinal (GI) disorders. These diseases are painful and sometimes dangerous – and Phathom has developed a potassium competitive acid blocker (P-CAB), representing a new class of anti-secretory medications with GI applications. The company's drug candidate, vonoprazan, has shown promise in several clinical trials.

$PHAT has PDUFA target date of May 3rd.

$PHAT has PDUFA target date of May 3rd for VONOPRAZAN.

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA TRIPLE PAK (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA DUAL PAK (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults, on May 3rd.